Bespoke Extracts, Inc.

BSPK

None; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001409197


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $359,088
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Apr 21, 2025 547 days before the rescan; latest periodic filing 10-Q received Nov 12, 2025

Letter at every rescan, 2026 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 21, 2025

a Nevada corporation. The Company's Common Stock (as hereinafter defined) is traded in the United States on the OTCQB (the "OTCQB") under the symbol "BSPK." The Company has one wholly-owned subsidiary, Bespoke Extracts Colorado, LLC ("Bespoke Colorado"). Bespoke began operations in the cannabis industry in 2023 upon the acquisition of a state-licensed adult-use marijuana infused products business in Aurora, Colorado. The Company has since begun producing pre-rolled marijuana cigarettes, or "pre-rolls".

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 2.0						
Gross profitability	126.1%	32.3%		2.2	371	2024-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(209.6%)	(6.6%)		1.8	812	2024-12-31
Gross margin stability, five years	not computable	2.8 pts				
five consecutive annual gross margins are required						
Solvency, sleeve percentile 98.5						
Twelve-month failure probability	not computable	0.06%				
market price is missing at 2025-09-30						
Altman Z double-prime	(276.64)	(0.30)		99.2	757	2024-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2020-08-31; latest annual assets end 2024-12-31						
Current ratio	0.15x	2.96x		97.9	840	2024-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.1%				
four consecutive annual observations are required						
Net share issuance, one year	not computable	2.5%				
raw and split-adjusted prices do not align at 2025-03-27						

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 6 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	8.0%	
Distance from 52-week high	not computable	(31.9%)	
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	not computable	(0.13)	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2024-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	342 (10-Q received Nov 12, 2025)
Median daily dollar volume, 63 sessions	n/a

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$452,935	2024-12-31	2025-04-21	10-K	25-033608
2	assets	us-gaap:Assets	$359,088	2024-12-31	2025-04-21	10-K	25-033608
3	net income	us-gaap:NetIncomeLoss	-$1.0M	2024-12-31	2025-04-21	10-K	25-033608
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$289,802	2024-12-31	2025-04-21	10-K	25-033608
5	assets	us-gaap:Assets	$354,360	2023-12-31	2025-04-21	10-K	25-033608
6	current assets	us-gaap:AssetsCurrent	$165,257	2024-12-31	2025-04-21	10-K	25-033608
7	current liabilities	us-gaap:LiabilitiesCurrent	$1.1M	2024-12-31	2025-04-21	10-K	25-033608
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$26.4M	2024-12-31	2025-04-21	10-K	25-033608
9	operating income	us-gaap:OperatingIncomeLoss	-$994,628	2024-12-31	2025-04-21	10-K	25-033608
10	book equity	us-gaap:StockholdersEquity	-$2.1M	2024-12-31	2025-04-21	10-K	25-033608
11	liabilities	us-gaap:Liabilities	$2.5M	2024-12-31	2025-04-21	10-K	25-033608
12	operating income	us-gaap:OperatingIncomeLoss	-$4.0M	2020-08-31	2021-12-13	10-K	21-065002
13	interest expense	us-gaap:InterestExpense	$535,688	2020-08-31	2021-12-13	10-K	21-065002
14	revenue	us-gaap:Revenues	$1.1M	2024-12-31	2025-04-21	10-K	25-033608
15	revenue	us-gaap:Revenues	$785,453	2023-12-31	2025-04-21	10-K	25-033608
16	revenue	us-gaap:Revenues	$3,407	2022-12-31	2024-04-18	10-K	24-033935
17	revenue	us-gaap:Revenues	$62,103	2019-08-31	2019-12-16	10-K	19-026230
18	assets	us-gaap:Assets	$409,591	2022-12-31	2024-04-18	10-K	24-033935
19	assets	us-gaap:Assets	$124,520	2021-08-31	2021-12-13	10-K	21-065002
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,153,220	2025-03-27	2025-04-21	10-K	25-033608
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,168,552	2024-03-31	2024-04-18	10-K	24-033935

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.